vertex posit phase result triplet combo reinforc
page full analyst note
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research
estim may
price data jan
rate updat jan
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
vertex pharmaceut best known
discov incivek blockbust hepat viru drug futur
tie robust cystic fibrosi portfolio approv
treatment kalydeco orkambi well addit pipelin
asset expect creat domin franchis lucr
abl
kalydeco success launch vertex well
posit cf genet disord affect approxim
peopl world-wide character progress deadli declin
lung function number target patient small
command six-figur price
disease-modifi drug seriou orphan indic drug
launch price close treatment
less cf suffer certain genet mutat
name gate mutat despit aggress price
major patient popul alreadi captur
vertex pipelin strategi develop drug known
corrector work combin kalydeco order treat
genet subtyp make larger portion cf patient
orkambi combo regimen approv
treat peopl common cf mutat
homozyg repres half cf popul
anticip vertex reach billion-plu peak sale
patient segment alon especi approv
next-gener combo symdeko year impress
result triplet combin pave way vertex
next-biggest opportun difficult-to-treat het/min cf patient
segment less third total cf popul
pois
dramat chang treatment cf earn firm
domin posit market world-wide chronic natur
therapi limit competit horizon heighten
market attract given posit market dynam
think vertex cf program could grow billion within
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
discov develop small-molecul drug
treatment seriou diseas key drug kalydeco orkambi
symdeko cystic fibrosi addit sever mid- late-stag
product target market vertex success develop
commerci two hiv proteas inhibitor outlicens
glaxosmithklin vertex pipelin also includ therapi treatment
cancer pain inflammatori diseas influenza rare diseas
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
vertex posit phase result triplet combo
vertex report posit result two phase studi
pipelin triplet combin cystic fibrosi
anticip chang fair valu
estim readout reinforc confid
combin tezacaftor ivacaftor met
primari endpoint patient popul test
heterozyg one mutat homozyg two
mutat combin demonstr toler
heterozyg patient
statist signific improv baselin lung
function percentag point homozyg
percentag point vertex orkambi symdeko doublet
combin alreadi treat homozyg patient
triplet encourag result could lead expand
elig patient popul stronger price power
vertex also report complet enrol two
phase studi differ triplet combin
tezacaftor ivacaftor data expect
first quarter anticip vertex file
best triplet
combin
maintain fair valu estim firm
per share valuat rest firm cystic
fibrosi program pipelin continu ramp-up
orkambi acceler
launch
next-gener symdeko tezacaftor kalydeco
biggest driver model homozyg
popul repres roughli cf patient
assum lower net price discount
 outsid larger
patient popul repres opportun
billion peak sale assum patient deter
orkambi risk/benefit profil captur
effect safer symdeko
second-largest
heterozyg popul cystic fibrosi patient
attribut probabl success tripl
combin regimen kalydeco two corrector
molecul full market launch model
probability-adjust peak sale billion
kalydeco monotherapi larg satur cf
popul gate mutat
howev late-stag competit sight
believ small opportun label expans
margin price increas gener peak sale close
billion vertex prove success expand
drug label genet subtyp includ nearli
potenti cystic fibrosi patient
origin approv price assumpt kalydeco
roughli per year
rest word versu current list price
cancer influenza pain
spinal cord injuri -- probabl approv less
base earlier stage develop overal
think vertex top line averag compound annual
growth next five year driven primarili
blockbust sale cf franchis think rise
product sale propel firm profit
ultim drive oper margin
return invest capit
bull case consid impact increas
annual price orkambi upcom triplet regimen
rais probabl triplet approv
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
statu cystic fibrosi market kalydeco launch
orkambi combin
next-gener symdeko
reach market year
disease-modifi drug market kalydeco
orkambi symdeko make backbon cf
therapi believ vertex remain leader
rare-diseas space forese futur
given limit treatment option cystic fibrosi
chronic natur diseas vertex abl command
strong price power cours patient life
kalydeco cost close treatment less
cf suffer certain genet mutat
despit aggress price uptak swift
almost elig patient therapi vertex
strategi develop drug known corrector
work combin kalydeco order treat
genet subtyp make larger portion cf
patient orkambi symdeko treat peopl
common cf mutat homozyg drug
price per year current target roughli
cf popul pediatr label expans
increas target popul approxim
patient firm cf pipelin drug includ
second-gener corrector use
combin kalydeco potent treatment
difficult-to-treat cf subtyp approv triple-combin
regimen use next-gener corrector pivot
test would expos vertex next-largest opportun
cf -- het/min patient compos nearli
cf genet disord affect roughli peopl
world-wide caus progress deadli declin
lung function number patient small
six-figur price vertex disease-modifi drug
make megablockbust market potenti addit
experienc welcom
heterozyg patient group increas
probabl approv rest vertex non-cf
pipelin case fair valu estim increas
per share return invest capit grow
bear case assum compani combin
therapi difficult-to-treat heterozyg
patient stumbl price pressur caus firm
cut price orkambi futur therapi
case think compani valu would fall per
share return invest capit pressur
believ vertex current relianc limit rang
market product center one therapeut area
warrant medium uncertainti rate given pipelin
vertex portfolio disease-modifi drug form
basi narrow econom moat rate compani
well support lengthi patent protect first-mov
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
commerci regulatori environ due lack
treatment sever afflict chronic natur
therapi limit competit near-term horizon
heighten market attract patent
kalydeco orkambi extend
respect european union
ward gener competit galapago partnership
remain closest pipelin threat vertex
cf franchis still year away reach
market give vertex time entrench current
market therapi cf prescrib popul also
potenti launch second-gener product
element lead us award compani narrow moat
rate
transform
execut
number pipelin drug target cancer partnership
merck pain spinal cord injuri influenza
partnership johnson johnson earli
say whether prospect becom signific
revenu driver believ vertex ampl potenti
diversifi cf portfolio would bolster moat
advantag firm exit hepat market
due incivek precipit declin limit non-cf
pipelin vertex depend cf franchis key
risk posit moat trend opportun
develop anticip howev firm
aggress invest early-stag pipelin beyond cf
enough cash target tuck-on acquisit
assign vertex posit moat trend rate base
promis clinic result pipelin product lack
near-term competit cystic fibrosi allow
domin attract market compani
demonstr abil intern develop success
market drug kalydeco orkambi boost
confid drug candid recent termin
novarti phase potenti drug mean galapago
partner remain major medium-term
threat howev phase candid face sever
year clinic trial need demonstr clearli
superior efficaci and/or safeti profil kalydeco
orkambi symdeko order impact vertex
commerci momentum also phase
cystic fibrosi drug ataluren note therapi
target small percentag cf popul
nonsens mutat overlap
beyond cf vertex remain pipelin candid
rel uncertain opportun compani
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
oth firm cf program pois domin
lucr market forese futur base
disease-modifi potenti drug chronic
use patient limit competit
overtex record success launch drug
differenti emerg biotech
often falter commerci
lead drug candid mostli
discov in-hous lend credibl drug-
discoveri technolog potenti gener
overtex valuat rest cf pipelin
compani could fail diversifi beyond cf
oth sky-high price orphan drug like kalydeco
unsustain particularli price-consci european
vertex nich cystic fibrosi market
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
year-end vertex nearli billion cash
million debtlik leas oblig like
biotechnolog compani vertex histor oper
loss high cost clinic trial
research loss financ larg
offer equiti debt secur collabor
fund arrang develop mileston
royalti partner howev success
launch orkambi kalydeco compani
abl gener signific revenu allow
build signific cash cushion suffici fund
develop commerci remain
development-stag candid even orkambi launch
still ramp expect vertex reach
sustain profit gener signific
cash flow thereaft expect vertex use
cash build diversifi rare-diseas portfolio
look beyond cystic fibrosi market
compani futur reli emerg cf franchis
signific amount vertex fair valu hing
commerci success orkambi larg
homozyg patient popul although expect
drug larg captur patient popul
disease-modifi drug market increas
patient discontinu orkambi due bronchospasm
side effect would curtail posit view firm
growth prospect moat trend addit
increas competit cf develop pipelin
could threaten vertex current leadership posit
progress vertex next-gener doublet candid
display bronchospasm effect
help mitig risk assumpt high price
underpin view blockbust potenti cf
market
payer
particularli austerity-strap govern europ may
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
efficaci
balk high price even drug treat orphan
indic nation institut
excel initi deni reimburs
cost-effect concern hand
kalydeco current price maintain
futur combin therapi much larger
number patient estim may prove
conserv firm risk compound
early-stag natur remain pipelin includ
experiment treatment influenza pain cancer
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
ceo/chairman board/
repres date owner name posit common share held report holder issuer
capit research manag compani
fidel manag research compani
share
fund
share
fund
rate jeffrey leiden becam ceo chairman
serv board two year previous
work presid
manag director life scienc ventur capit
firm believ experi particularli stint
pharma asset compani launch
new drug priorit pipelin inde incivek
launch quit success
particularli consid commerci issu
commonli affect emerg biotech firm
howev think investor would better serv
compani separ ceo chairman role
addit think manag compens
histor high although recent measur spur
sharehold vote curtail amount go forward
leiden total compens million
sever senior manag compens packag
million respons sharehold disapprov
previous excess amount compani also
probe secur exchang commiss
seri larg insid stock sale posit clinic news
past year cfo sold vest
hold compani stock surg
promis result cf trial sale
appropri took place prearrang stock-sel
plan question manag long-term prioriti
incent insid abl will sell materi
amount stock rather maintain sharehold
long-term investor
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
manag rais full-year revenu guidanc
midpoint billion midpoint billion
thank better-than-anticip adopt new
combin regimen adjust rapid uptak
model expect materi chang fair
valu estim per share continu believ
firm posit cystic fibrosi warrant narrow
econom moat posit moat trend
although success launch symdeko cannib
orkambi sale expect symdeko expand
elig treatment popul captur patient
previous discontinu treatment orkambi well
patient naiv vertex combin expect firm
stretch elig popul new corrector
molecul anticip
launch second half approv
furthermor result food drug administr
approv kalydeco orkambi younger patient
environ remain tough non-u payer
unit kingdom franc australia
due expens price tag vertex treatment
believ firm success negoti reimburs
rare diseas lean superior efficaci
treatment regimen lack altern treatment
cystic fibrosi portfolio steal spotlight vertex
well posit diversifi pipelin therapi pain
partnership crispr sickl cell
diseas addit healthi accumul cash
august
vertex cystic fibrosi franchis post solid result
vertex third-quart result mostli line
expect million revenu repres
growth last year thank year launch
symdeko unit state continu uptak
cystic fibrosi doublet tweak full-year
revenu assumpt vertex portfolio toward
higher end manag reiter revenu guidanc
forese materi chang fair valu
estim per share
readout vertex
signific near-term catalyst firm approach
anticip
combin regimen expect end year
competit combin therapi cystic fibrosi
thicken lacklust data galapago
vertex closest competitor late june
recent promis octob readout doublet therapi
proteostasi proteostasi expect
provid preliminari data compet triplet therapi
year-end highlight import vertex upcom
readout note vertex cystic fibrosi portfolio
captur signific patient share benefit first-
mover advantag space given strong portfolio
diversifi early-stag pipelin reiter
narrow-moat rate posit moat trend
firm end quarter billion cash
equival believ posit firm well
deal would build pipelin
vertex pharmaceut portfolio cystic fibrosi
treatment remain strong post total revenu
growth second quarter driven next-gener
molecul symdeko approv februari
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
